View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Theme
  2. Macro
  3. Covid-19
June 17, 2020

MHRA suspends recruitment for all UK hydroxychloroquine trials

By Allie Nawrat

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has instructed all UK trials investigating hydroxychloroquine in Covid-19 to suspect recruitment.

This follows on from the University of Oxford RECOVERY trial halting recruitment into its hydroxychloroquine arm because results found it provided no clinical benefit to hospitalised Covid-19 patients.

MHRA CEO Dr June Raine said: “We have told those conducting clinical trials using hydroxychloroquine to treat or prevent COVID-19 to suspend recruitment into their trials.

“Neither hydroxychloroquine nor chloroquine are licensed to treat COVID-19 related symptoms or to prevent infection.

“It is important to note that patients taking hydroxychloroquine and chloroquine to treat other health conditions can continue to do so, as advised by their healthcare professional, as the balance of benefits and risks remains favourable in the licensed uses.”

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology